Supplementary Information

Σχετικά έγγραφα
Lee et al., Suppl. Fig. 1

Figure S1: Deletion of Dlx3 in the NC A) LacZ staining of Dlx3 LacZ/WT mice (a) and Wnt1- cre:r26r LacZ mice (b) at E11.5. The arrowhead points at

Supplemental Table S1. Tumor specific networks are enriched with somatically mutated genes (taken from the database COSMIC)

Supplementary Table S1. Primary antibodies for Western blot analysis. Antibody name and specifications

Supplemental Table 1. Oligonucleotides used to identify H-RAS, K-RAS and N-RAS mutations and PTEN gene expression.

NES: normalized enrichment score (analyzed using KEGG pathway gene sets in the GSEA software); FDR:

Μελέτη της έκφρασης του ογκοκατασταλτικού γονιδίου Cyld στον καρκίνο του μαστού

TFDP2 TFDP1 SUMO1 SERTAD1 RPA3 RBBP8 RAD9A RAD17 RAD1 NBN MRE11A MNAT1 KPNA2 KNTC1 HUS1 HERC5 GTSE1 GTF2H1 GADD45A E2F4 DNM2 DDX11 CUL3 SKP2 RBL1 RB1

SUPPLEMENTARY INFORMATION

RARα2 expression confers myeloma stem cell features. Ye Yang, Jumei Shi, Giulia Tolomelli, Hongwei Xu, Jiliang Xia, He Wang, Wen Zhou, Yi Zhou,

Supplementary Material: Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis

Retinoic Acid Mediates Visceral-specific Adipogenic Defects of Human Adipose-derived Stem Cells

Cellular Physiology and Biochemistry

OncoNext TM Risk-Oncoscreening

encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ

The following primers were used for RT-PCR: GAPDH forward (Fw) 5 -GAA GGT GAA GGT

A strategy for the identification of combinatorial bioactive compounds. contributing to the holistic effect of herbal medicines

MSM Men who have Sex with Men HIV -

Identification of Fish Species using DNA Method

Nature Medicine doi: /nm.2457

Pax8 and Pax2 are specifically required at different steps of Xenopus pronephros development

SUPPLEMENTARY INFORMATION

TABLE OF CONTENTS Page

Αξιοποίηση Φυσικών Αντιοξειδωτικών στην Εκτροφή των Αγροτικών

Christopher Stephen Inchley, 2015

Molecular evolutionary dynamics of respiratory syncytial virus group A in

< (0.999) Graft (0.698) (0.483) <0.001 (0.698) (<0.001) (<0.001) 3 months (0.999) (0.483) (<0.001) 6 months (<0.

Supplementary Information Titles

Does anemia contribute to end-organ dysfunction in ICU patients Statistical Analysis

Supporting Information

SUPPLEMENTARY INFORMATION. Supplemenary Figures Figure S1

encouraged to use the Version of Record that, when published, will replace this version. The most /BCJ BIOCHEMICAL JOURNAL

ΕΦΑΡΜΟΓΗ ΕΥΤΕΡΟΒΑΘΜΙΑ ΕΠΕΞΕΡΓΑΣΜΕΝΩΝ ΥΓΡΩΝ ΑΠΟΒΛΗΤΩΝ ΣΕ ΦΥΣΙΚΑ ΣΥΣΤΗΜΑΤΑ ΚΛΙΝΗΣ ΚΑΛΑΜΙΩΝ

CRASH COURSE IN PRECALCULUS

NCBI ID Symbol 2 A2M A4GALT A4GNT 8086 AAAS 13 AADAC AADACL AAGAB 15 AANAT 16 AARS AARS AASS 18 ABAT 19 ABCA1

Homework 3 Solutions

Second Order RLC Filters

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ

Supplementary Table S1 Demographic characteristics of HCC patients


ΕΘΝΙΚΟ ΜΕΤΣΟΒΙΟ ΠΟΛΥΤΕΧΝΕΙΟ ΣΧΟΛΗ ΗΛΕΚΤΡΟΛΟΓΩΝ ΜΗΧΑΝΙΚΩΝ ΚΑΙ ΜΗΧΑΝΙΚΩΝ ΥΠΟΛΟΓΙΣΤΩΝ

«ΑΓΡΟΤΟΥΡΙΣΜΟΣ ΚΑΙ ΤΟΠΙΚΗ ΑΝΑΠΤΥΞΗ: Ο ΡΟΛΟΣ ΤΩΝ ΝΕΩΝ ΤΕΧΝΟΛΟΓΙΩΝ ΣΤΗΝ ΠΡΟΩΘΗΣΗ ΤΩΝ ΓΥΝΑΙΚΕΙΩΝ ΣΥΝΕΤΑΙΡΙΣΜΩΝ»

Η ΨΥΧΙΑΤΡΙΚΗ - ΨΥΧΟΛΟΓΙΚΗ ΠΡΑΓΜΑΤΟΓΝΩΜΟΣΥΝΗ ΣΤΗΝ ΠΟΙΝΙΚΗ ΔΙΚΗ

ΓΕΩΠΟΝΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΤΜΗΜΑ ΑΓΡΟΤΙΚΗΣ ΟΙΚΟΝΟΜΙΑΣ & ΑΝΑΠΤΥΞΗΣ

Correlation of nonsilent somatic mutations with the age and the disease stage of 25 people with NKTCL, subjected to whole-exome sequencing.

Single-site association results for 136 SCARB1 genotyped variants with HDL-C.

Si + Al Mg Fe + Mn +Ni Ca rim Ca p.f.u

ΠΕΡΙΕΧΟΜΕΝΑ. Κεφάλαιο 1: Κεφάλαιο 2: Κεφάλαιο 3:

Supplementary Table 1. Primer sequences used for RT-qPCR validation of the microarray data. Primer. direction. Forward

7KH VHQVLWLYLW\ RI UDGLRWKHUDS\ WR WLVVXH FRPSRVLWLRQ DQG LWV HVWLPDWLRQ XVLQJ QRYHO GXDO HQHUJ\ &7 PHWKRGV Guillaume Landry

Nature Immunology: doi: /ni Supplementary Figure 1. IL-6 reporter mice.

Supplementary Materials for

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΓΕΩΠΟΝΙΚΩΝ ΕΠΙΣΤΗΜΩΝ ΒΙΟΤΕΧΝΟΛΟΓΙΑΣ ΚΑΙ ΕΠΙΣΤΗΜΗΣ ΤΡΟΦΙΜΩΝ. Πτυχιακή εργασία

IL - 13 /IL - 18 ELISA PCR RT - PCR. IL - 13 IL - 18 mrna. 13 IL - 18 mrna IL - 13 /IL Th1 /Th2

w o = R 1 p. (1) R = p =. = 1

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΤΜΗΜΑ ΝΟΣΗΛΕΥΤΙΚΗΣ

HOMEWORK 4 = G. In order to plot the stress versus the stretch we define a normalized stretch:

CPT. Tsuchiya. beta. quantitative RT PCR QIAGEN IGFBP. Fect Transfection Reagent sirna. RT PCR RNA Affymetrix GeneChip Expression Array

«ΧΑΡΑΚΤΗΡΙΣΜΟΣ ΜΕΤΑΓΡΑΦΙΚΩΝ ΜΟΝΟΠΑΤΙΩΝ ΠΟΥ ΣΥΝΔΕΟΝΤΑΙ ΜΕ ΤΗΝ ΑΛΛΕΡΓΙΑ (ΑΝΑΦΟΡΑ)»

Supplementary Table 1. Primers used for RT-qPCR analysis of striatal and nigral tissue.

Study of urban housing development projects: The general planning of Alexandria City

Αποστήματα του φάρυγγα στα παιδιά

Δεδομένα ασφάλειας του certolizumab pegol από τα αρχεία της UCB

VBA Microsoft Excel. J. Comput. Chem. Jpn., Vol. 5, No. 1, pp (2006)

Introduction to Bioinformatics

Table of Contents 1 Supplementary Data MCD

Burden of Disease Variants in Participants of the Long Life Family Study. Supplemental Online Material

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΤΜΗΜΑ ΝΟΣΗΛΕΥΤΙΚΗΣ

Product Name Code Size Application

HIV HIV HIV HIV AIDS 3 :.1 /-,**1 +332

Comparison of Evapotranspiration between Indigenous Vegetation and Invading Vegetation in a Bog

Supporting Information

ΠΟΛΥΤΕΧΝΕΙΟ ΚΡΗΤΗΣ ΣΧΟΛΗ ΜΗΧΑΝΙΚΩΝ ΠΕΡΙΒΑΛΛΟΝΤΟΣ

[1] P Q. Fig. 3.1

LAPTM4B is associated with poor prognosis in NSCLC and promotes the. NRF2-mediated stress response pathway in lung cancer cells

CHAPTER 25 SOLVING EQUATIONS BY ITERATIVE METHODS

Μοριακή Διαγνωστική. Σύγχρονες Εφαρμογές Μοριακής Διαγνωστικής. Κλινική Χημεία ΣΤ Εξάμηνο - Παραδόσεις

Supplementary figures

Chapter 6 BLM Answers

Μαρία Κατσιφοδήμου. Ο ρόλος της έκκρισης HLA-G από τα ανθρώπινα έμβρυα στην επιτυχία της εξωσωματικής γονιμοποίησης. Μεταπτυχιακή Διπλωματική Εργασία

Queensland University of Technology Transport Data Analysis and Modeling Methodologies

Comparison of carbon-sulfur and carbon-amine bond in therapeutic drug: -S-aromatic heterocyclic podophyllum derivatives display antitumor activity

Mean bond enthalpy Standard enthalpy of formation Bond N H N N N N H O O O

Γεωπονικό Πανεπιςτήμιο Αθηνών Τμήμα Αξιοποίηςησ Φυςικών Πόρων και Γεωργικήσ Μηχανικήσ

Econ 2110: Fall 2008 Suggested Solutions to Problem Set 8 questions or comments to Dan Fetter 1

ΤΕΧΝΟΛΟΓΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ. Πτυχιακή διατριβή. Ονοματεπώνυμο: Αργυρώ Ιωάννου. Επιβλέπων καθηγητής: Δρ. Αντρέας Χαραλάμπους

Appendix to On the stability of a compressible axisymmetric rotating flow in a pipe. By Z. Rusak & J. H. Lee

Salmonella produce microrna-like RNA fragment Sal-1 in the infected cells to. facilitate intracellular survival

Η ΕΠΙΔΡΑΣΗ ΤΗΣ ΑΙΘΑΝΟΛΗΣ,ΤΗΣ ΜΕΘΑΝΟΛΗΣ ΚΑΙ ΤΟΥ ΑΙΘΥΛΟΤΡΙΤΟΤΑΓΗ ΒΟΥΤΥΛΑΙΘΕΡΑ ΣΤΙΣ ΙΔΙΟΤΗΤΕΣ ΤΗΣ ΒΕΝΖΙΝΗΣ


ΠΕΡΙΕΧΟΜΕΝΑ. Μάρκετινγκ Αθλητικών Τουριστικών Προορισμών 1

Supplementary Figure 1

Για να ελέγξουµε αν η κατανοµή µιας µεταβλητής είναι συµβατή µε την κανονική εφαρµόζουµε το test Kolmogorov-Smirnov.

ΕΟΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΤΟΜΕΑΣ ΜΟΡΦΟΛΕΙΤΟΥΡΓΙΚΟΣ ΕΡΓΑΣΤΗΡΙΟ ΙΣΤΟΛΟΓΙΑΣ & ΕΜΒΡΥΟΛΟΓΙΑΣ

ΑΡΙΣΤΟΤΕΛΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΟΝΙΚΗΣ ΙΑΤΡΙΚΗ ΣΧΟΛΗ. ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥ ΩΝ «Ιατρική Ερευνητική Μεθοδολογία» ΙΠΛΩΜΑΤΙΚΗ ΕΡΓΑΣΙΑ

Group 2 Methotrexate 7.5 mg/week, increased to 15 mg/week after 4 weeks. Methotrexate 7.5 mg/week, increased to 15 mg/week after 4 weeks

Supplementary Materials: A Preliminary Link between Hydroxylated Metabolites of Polychlorinated Biphenyls and Free Thyroxin in Humans

Math 6 SL Probability Distributions Practice Test Mark Scheme

ΠΑΡΑΜΕΤΡΟΙ ΕΠΗΡΕΑΣΜΟΥ ΤΗΣ ΑΝΑΓΝΩΣΗΣ- ΑΠΟΚΩΔΙΚΟΠΟΙΗΣΗΣ ΤΗΣ BRAILLE ΑΠΟ ΑΤΟΜΑ ΜΕ ΤΥΦΛΩΣΗ

Electronic Supplementary Information (ESI)

Transcript:

Supplementary Information Recurrent PAX3-MAML3 Fusion in Biphenotypic Sinonasal Sarcoma Xiaoke Wang 1,, Krista L. Bledsoe 2,, Rondell P. Graham 1,, Yan W. Asmann 3, David S. Viswanatha 1, Jean E. Lewis 1, Jason T. Lewis 1, Margaret M. Chou 4, Michael J. Yaszemski 5, Jin Jen 6, Jennifer J. Westendorf 5, André M. Oliveira 1, 5 1 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 2 Mayo Graduate School, Rochester, Minnesota 3 Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida 4 Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and the Perelman School of Medicine, Philadelphia, Pennsylvania 5 Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota 6 Medical Genome Facility, Center of Individualized Medicine, Mayo Clinic, Rochester, Minnesota These authors contributed equally to this work. Supplementary Figure 1... 2 Supplementary Figure 2... 3 Supplementary Figure 3.... 4 Supplementary Figure 4... 5 Supplementary Figure 5... 6 Supplementary Table 1... 7 Supplementary Table 2... 8 Supplementary Table 3... 13 Supplementary Table 4... 18 Supplementary Table 5... 34 1

Supplementary Figure 1. Cytogenetics and molecular genetic findings for the PAX3-MAML3 fusion. (a) Partial karyogram showing the chromosomal translocation t(2;4)(q35;q31.1). (b) and (c) FISH break apart strategy shows rearrangements of PAX3 and MAML3 loci, respectively (see also Fig. 1b). The percentage of rearranged cells for these loci ranged from 25 to 78% (median, 60%). Endothelial cells, inflammatory cells, sinonasal epithelial cells and other nonneoplastic cells showed no rearrangement of these loci. (d) Representative RT-PCR gel showing the fusion PAX3-MAML3 in three examples of SNS (lanes 1-3). Several other tumors (lanes 4-8: alveolar rhabdomyosarcoma, dermatofibrosarcoma protuberans, melanoma, malignant peripheral nerve sheath tumor and synovial sarcoma, respectively) and normal sinonasal tissue (lane 9) were negative for the fusion product; lanes 10-11: no template; see also Supplementary Table 2). (e) Confirmatory chromatogram showing the PAX3-MAML3 sequence at the fusion breakpoint in case 1. 2

Supplementary Figure 2. The PAX3-MAML3 fusion protein localizes to the nucleus and binds DNA. (a) Western blots were performed with anti-pax3 or tubulin antibodies on lysates of HEK293T cells expressing pcdna3 (Co), FLAG-PAX3-MAML3 (P-M) or HA-PAX3. (b) Immunofluorescence images showing nuclear expression of FLAG-PAX3-MAML3 in C2C12 cells. Cells were counterstained with phalloidin to detect cytoplasmic F-actin and with DAPI to detect DNA. (c) Electrophoretic mobility shift assay (EMSA) of FLAG-PAX3-MAML3 binding to double-stranded DNA containing a PAX3 binding element. Lysates from COS-7 cells expressing FLAG-PAX3-MAML3 (P-M) or HA-PAX3 were incubated with a 32 P-labeled PAX3 DNA probe in the presence or absence of 100-fold excess of the wildtype (WT) probe, a mutated (Mut) probe, control IgG, anti-ha or anti-flag. The arrow points to PAX3- MAML3/DNA complexes. The arrowhead indicates PAX3/DNA complexes. The asterisk indicates the free probe. (d) Transient transcription assays demonstrating the effect of PAX3- MAML3 on a Notch reporter, Hes5p-Luc, in C2C12 cells in the presence or absence of the Notch 1 intracellular domain 1 (NICD1). * p < 0.01, ** p < 0.0001 relative to control in unpaired t-tests. 3

Supplementary Figure 3. Pathway enrichment analysis. (a) Gene ontology analysis shows that SNS expression profile is enriched in genes involved in several developmental processes, including skeletal system morphogenesis and general organ development (minimum p = 3.39x10-14 for skeletal system morphogenesis, false discovery rate (FDR) = 1.37x10-10 ; maximum p = 1.14x10-10 for organ morphogenesis, FDR = 4.64x10-8 ) (b) Enrichment process network analysis shows that SNS exhibits differential expression of several biologic circuits involved in neural, cardiac, bone and other developmental processes (minimum p = 4.19x10-4 for neural development, FDR = 0.058; maximum p = 0.031 for olfactory transduction, FDR = 0.427). Enrichment analyses were performed using the MetaCore gene regulatory network database in order to identify networks that are significantly enriched by differentially expressed genes. Modified gene ontology terms are based on the GO database (www.geneontology.org). 4

Supplementary Figure 4. Representative qpcr and immunohistochemistry studies confirm differential gene expression in SNS. (a) and (b) High expression of NTRK3 and MYOD1 were observed in most examples of SNS. (c) MLANA and MITF (not shown) were not expressed in SNS. (d) NTRK3 showed a strong membranous pattern of expression in virtually all SNS (24/25). No staining was observed in the sinonasal epithelium. (e) MYOD1 nuclear expression was focal in a few SNS tumors (4/25); arrow indicating an example cell with focal MYOD1 expression. (f) Melan A and MITF (not shown) were universally negative in all SNS tested (n=22). qpcr and/or immunohistochemistry also confirmed the overexpression of PLUNC, PCP4, GDF7, PIK3C2G, ALX1 and PAX3, and downregulation of HOXB7 (data not shown; see also Supplementary Table 1; additional information about the phenotype of SNS can be found in ref. 1) (RE, relative expression; SNS, sinonasal sarcoma (n=5); NST, normal sinonasal tissue (n=4); ARMS, alveolar rhabdomyosarcoma (n=3); DFSP, dermatofibrosarcoma protuberans (n=3); MPNST, malignant peripheral nerve sheath tumor (n=3); SS, synovial sarcoma (n=3). *** and ** indicate Kruskal- Wallis test p < 0.01 and p < 0.05, respectively, and post hoc Dunett s test p < 0.05; * indicates Wilcoxon-Mann-Whitney test p < 0.05; error bars represent mean ± SD). 5

Supplementary Figure 5. Differential expression of myogenin between SNS and ARMS. (a) Biphenotypic sinonsal sarcoma (SNS) is a monomorphic spindle cell neoplasm that exclusively occurs in the head and neck region of middle aged individuals, most commonly females (HE x100). (b) ARMS is a pediatric small round cell tumor that shows a characteristic pseudoalveolar growth pattern (HE x100). (c-d) qpcr and immunohistochemical analysis show that while all ARMS (n = 11) express high levels of MYOG (myogenin) mrna (c) and protein (d, inset), SNS (n = 11) is consistently negative for this marker (c/d); * indicates Wilcoxon-Mann-Whitney test p < 0.0001; error bars represent mean ± SD). 6

Supplementary Table 1. Summary of Clinical Features, Immunophenotype and Molecular Findings in Biphenotypic Sinonasal Sarcoma Case Sex Age Location PAX3-MAML3 PAX3 MAML3 Phenotype Profile # (RT-PCR) (FISH) (FISH) PAX3 S100 Actin NTRK3 MyoD1 Myogenin Desmin Melan A LR LR (mo) OS (mo) 1^ Δ F 47 ethmoid/cribriform + + + + F+ - + F+ - F+ - Y 10 12 2^ M 74 ethmoid/orbit + + + + + + + - - - - - - - 3 F 42 nasal/ethmoid + + + + + + + - - - - N 60 60 4* F 47 nasal/ethmoid + + - + + + + - - - - - - - 5 F 47 ethmoid/nasal cavity + + + + F+ + + - - - - - - - 6** F 57 ethmoid - + - + F+ + + - - - - - - - 7 F 24 ethmoid/sphenoid + + + + F+ + + - - - - Y 60 60 8 M 39 nasal cavity + + + + + F+ + - - - - N 32 32 9** F 26 nasal cavity - + - + F+ - + - - - - N 18 18 10 F 85 sphenoid + + + + + + + - - - - Y 12 12 11 F 45 nasal cavity + + + + F+ + + F+ - - - N 48 48 12 F 51 nasal cavity + + + + + + + - - F+ - N 42 42 13* F 32 nasal cavity + + - + + + + F+ - - - N 36 36 14** F 47 nasal cavity - + - + + F+ + - - - - - - 15** F 46 ethmoid - + - + + + + - - - - N 26 26 16 F 58 frontal/ethmoid + + + + F+ + - - - F+ - Y 24 40 17 F 56 ethmoid + + + + + + + - - F+ - - - - 18 F 52 frontal/ethmoid + + + + F+ + + - - - - N 180 180 19** M 76 nasal cavity - + - ND + + + ND ND ND ND N 12 12 20 F 49 nasal cavity + + + + + + + - - - - N 25 25 21*** M 46 nasal cavity/ethmoid/frontal - - + + F+ + + - - - - N 336 336 22* F 38 nasal cavity + + - + + F+ F+ - - - - Y 13 20 23 M 56 ethmoid + + + ND + + + ND ND - ND - - - 24 F 66 ethmoid + + + + + + + F+ - - - - - - 25 M 61 nasal cavity + + + + + ND + ND ND ND ND - - - +, positive; -, negative; Y, yes; N, not observed; LR, local recurrence; OS, overall survival; mo, months; ND, not done due to lack of material; F, focal positivity (<30% of total tumor area). * Findings suggestive of a cryptic MAML3 locus rearrangement (cases 4, 13 and 22). ** Findings suggestive of alternate PAX3 fusion genes. *** Findings suggestive of an alternate MAML3 fusion gene. ^ Index case for cytogenetics. Karyotypes: 46,XX,t(2;4)(q35;q31.1)[22]/46,XX[7] (case 1) and 46,XX,t(2;4)(q35;q31.1)[cp20]/46,XX[3] (case 2). Index case used for transcriptome sequencing. Δ An alternate splicing variant of PAX3-MAML3 was found in this case (GenBank accession no. KF727277). #, immunohistochemical analysis for S100, actin (muscle specific actin and smooth muscle actin) and desmin were described in ref.1; all tumors were universally positive for ALX1 and negative for MITF, SILV, HMB45 and HES1. 7

Supplementary Table 2. Clinico-Pathologic Features and Molecular Profile of Control Tumors and Tissues Used in this Study Histologic Diagnosis Age Sex Location Molecular Profile PM(-) GEP qpcr IHC 1 Adrenal cortical carcinoma 43 F Adrenal - * 2 Alveolar rhabdomyosarcoma-01 7 F Forearm PAX3-FOXO1 * * * * 3 Alveolar rhabdomyosarcoma-02 21 F Periorbital PAX3-FOXO1 * * * * 4 Alveolar rhabdomyosarcoma-03 1 M Thigh PAX3-FOXO1 * * * * 5 Alveolar rhabdomyosarcoma-04 9 F Lung, met. PAX3-FOXO1 * * * 6 Alveolar rhabdomyosarcoma-05 5 M Abdominal wall PAX3-FOXO1 * * * 7 Alveolar rhabdomyosarcoma-06 51 M Neck PAX3-FOXO1 * * * 8 Alveolar rhabdomyosarcoma-07 5 F Thigh PAX3-FOXO1 * * * 9 Alveolar rhabdomyosarcoma-08 7 M Sinus PAX3-FOXO1 * * * 10 Alveolar rhabdomyosarcoma-09 14 M Thigh PAX3-FOXO1 * * * 11 Alveolar rhabdomyosarcoma-10 7 F Pelvic area PAX3-FOXO1 * * * 12 Alveolar rhabdomyosarcoma-11 12 M Forearm PAX3-FOXO1 * * 13 Alveolar rhabdomyosarcoma-12 16 M Neck, met. PAX3-FOXO1 * * 14 Alveolar rhabdomyosarcoma-13 28 F Neck PAX3-FOXO1 * * 15 Alveolar rhabdomyosarcoma-14 57 F Neck PAX3-FOXO1 * * 16 Alveolar rhabdomyosarcoma-15 13 F Thigh PAX3-FOXO1 * * 17 Alveolar rhabdomyosarcoma-16 9 F Sinus PAX3-FOXO1 * * 18 Alveolar rhabdomyosarcoma-17 9 M Perirenal PAX3-FOXO1 * * 19 Alveolar rhabdomyosarcoma-18 14 F Inguinal area PAX3-FOXO1 * * 20 Alveolar rhabdomyosarcoma-19 7 F Calf PAX7-FOXO1 * * 21 Alveolar rhabdomyosarcoma-20 19 M Groin PAX3-FOXO1 * * 22 Alveolar rhabdomyosarcoma-21 51 M Neck PAX3-FOXO1 * * 23 Alveolar soft part sarcoma 35 F Pelvis ASPSCR1-TFE3 * 24 Angioleiomyoma 45 M Hand - * * 25 Angiomatoid fibrous histiocytoma 22 M Arm EWSR1-CREB1 * * 26 Breast adenocarcinoma, lobular type 48 F Breast - * 27 Chronic myelogenous leukemia cell line K562 - - - BCR-ABL * 28 Colon adenocarcinoma 83 M Colon, ascending - * 29 Colon adenocarcinoma 4 F Colon; FAP - * 30 Dedifferentiated liposarcoma 85 M Retroperitoneum - * * 31 Dermatofibroma/Benign fibrous histiocytoma-01 45 F Arm - * * * * 32 Dermatofibroma/Benign fibrous histiocytoma-02 46 F Arm - * * * * 33 Dermatofibroma/Benign fibrous histiocytoma-03 39 F Shoulder - * * * * 8

34 Dermatofibrosarcoma protuberans-01 53 F Chest wall - * * 35 Dermatofibrosarcoma protuberans-02 35 M Upper back - * * 36 Dermatofibrosarcoma protuberans-03 62 F Chest wall - * * 37 Dermatofibrosarcoma protuberans-04 60 M Chin - * * 38 Dermatofibrosarcoma protuberans-05 48 F Lower back COL1A1-PDGFB * * 39 Dermatofibrosarcoma protuberans-06 17 M Thigh - * * 40 Dermatofibrosarcoma protuberans-07 65 M Abdominal wall COL1A1-PDGFB * * 41 Desmoplastic small round cell tumor-01 21 M Abdomen EWSR1-WT1 * * * * 42 Desmoplastic small round cell tumor-02 27 M Abdomen EWSR1-WT1 * * * * 43 Desmoplastic small round cell tumor-03 8 M Abdomen EWSR1-WT1 * * * * 44 Embryonal rhabdomyosarcoma-01 45 F Axilla - * * 45 Embryonal rhabdomyosarcoma-02 7 M Epididymum - * * 46 Embryonal rhabdomyosarcoma-03 5 M Infratemporal - * * 47 Embryonal rhabdomyosarcoma-04 7 M Bladder - * * 48 Embryonal rhabdomyosarcoma-05 18 F Skull base - * * 49 Embryonal rhabdomyosarcoma-06 12 M Paratesticular - * * 50 Embryonal rhabdomyosarcoma-07 12 F Cheek - * * 51 Embryonal rhabdomyosarcoma-08 16 F Maxilla - * * 52 Embryonal rhabdomyosarcoma-09 5 F Skull base - * * 53 Embryonal rhabdomyosarcoma-10 8 M Shoulder - * * 54 Embryonal rhabdomyosarcoma-11 12 M Paratesticular - * * 55 Embryonal rhabdomyosarcoma-12 1 M Prostate - * * 56 Embryonal rhabdomyosarcoma-13 6 M Bladder - * * 57 Endometrial stromal sarcoma 34 F Uterus - * * 58 Ewing sarcoma-01 54 M Leg EWSR1-FLI1 * * * * 59 Ewing sarcoma-02 10 M Paraspinal EWSR1-FLI1 * * * * 60 Ewing sarcoma-03 24 F Abdomen EWSR1-FLI1 * * * * 61 Ewing sarcoma-04 17 F Neck EWSR1-FLI1 * 62 Ewing sarcoma-05 27 F Pelvis EWSR1-FLI1 * * 63 Ewing sarcoma-06 39 M Abdomen EWSR1-ERG * * 64 Ewing sarcoma-07 15 F Sinus EWSR1-FLI1 * 65 Fibroma of tendon sheath-01 69 M Hand - * * * * 66 Fibroma of tendon sheath-02 65 F Hand - * * * * 67 Fibroma of tendon sheath-03 77 M Hand - * * * * 68 Fibrosarcoma, adult-type-01 57 M Groin - * * 69 Fibrosarcoma, adult-type-02 91 F Mandible - * 9

70 Gastrointestinal stromal tumor-01 48 F Stomach KIT exon 11 mut. * * * * 71 Gastrointestinal stromal tumor-02 62 F Stomach KIT exon 11 mut. * * * * 72 Gastrointestinal stromal tumor-03 71 F Stomach KIT exon 11 mut. * * * * 73 Infantile fibrosarcoma 8w M Thigh ETV6-NTRK3 * * 74 Leiomyosarcoma-01 53 F Uterus - * * 75 Leiomyosarcoma-02 84 M Leg - * * 76 Leiomyosarcoma-03 71 M Leg * * 77 Malignant peripheral nerve sheath tumor-01 50 F Thigh - * * * * 78 Malignant peripheral nerve sheath tumor-02 42 F Leg - * * * * 79 Malignant peripheral nerve sheath tumor-03 38 M Neck; NF1 - * * * * 80 Malignant peripheral nerve sheath tumor-04 41 M Pelvis - * * 81 Malignant peripheral nerve sheath tumor-05 57 F Groin - * * 82 Malignant peripheral nerve sheath tumor-06 74 F Chest wall - * * 83 Malignant peripheral nerve sheath tumor-07 94 M Neck - * * 84 Malignant peripheral nerve sheath tumor-08 74 F Chest wall - * * 85 Malignant peripheral nerve sheath tumor-09 69 M Shoulder - * * 86 Melanoma-01 52 F Inguinal area, met. - * * * * 87 Melanoma-02 48 M Chest wall, met. - * * * * 88 Melanoma-03 80 M Arm - * * * * 89 Melanoma-04 80 F Arm - * 90 Melanoma-05 71 M Abdominal wall, met. - * 91 Melanoma-06 49 M Groin, met. - * 92 Melanoma-07 36 M Neck - * 93 Melanoma-08 57 M Mesentery, met. - * 94 Mucoepidermoid carcinoma-01 79 F Parotid gland CRCT1-MAML2 * * 95 Mucoepidermoid carcinoma-02 67 M Parotid gland CRCT1-MAML2 * 96 Myofibroblastic sarcoma 51 M Hypopharynx - * * 97 Myofibroma 34 M Chest wall - * * 98 Myxofibrosarcoma 70 M Chest wall - * * 99 Neurofibroma-1 31 F Sciatic nerve; NF1 - * * * * 100 Neurofibroma-2 62 M Chest wall - * * * * 101 Neurofibroma-3 57 F Chest wall - * * * * 102 Normal cardiac skeletal muscle-01 38 F - - * * 103 Normal cardiac skeletal muscle-02 56 M - - * 104 Normal parathyroid gland 70 F - - * 105 Normal sinonasal tissue-01 55 M R - * * * 10

106 Normal sinonasal tissue-02 50 F - - * * 107 Normal sinonasal tissue-03 63 M - - * * * 108 Normal sinonasal tissue-04 38 M - - * * * 109 Normal sinonasal tissue-05 31 M L - * * 110 Normal sinonasal tissue-06 31 M R - * * * 111 Normal sinonasal tissue-07 63 M - - * * 112 Normal sinonasal tissue-08 41 M - - * * * 113 Normal sinonasal tissue-09 68 F - - * * 114 Normal sinonasal tissue-10 69 M - - * * * 115 Normal sinonasal tissue-11 29 M - - * * * 116 Normal sinonasal tissue-12 37 M - - * * 117 Normal sinonasal tissue-13 55 M L - * * * 118 Normal skeletal muscle-01 59 M - - * * * 119 Normal skeletal muscle-02 65 F - - * * * 120 Osteosarcoma 3 M Femur - * * 121 Pleomorphic adenoma 55 M Submandibular gland - * * 122 Prostatic stromal sarcoma 54 M Prostate - * * 123 Schwannoma-01 35 F Spine, T7 - * * * * 124 Schwannoma-02 51 F Sciatic nerve - * * * * 125 Schwannoma-03 43 M Neck - * * * * 126 Spindle cell rhabdomyosarcoma 1 M Chest wall - * * 127 Synovial sarcoma-01 17 F Forearm SS18-SSX1 * * * * 128 Synovial sarcoma-02 19 M Finger SS18-SSX1 * * * * 129 Synovial sarcoma-03 76 M Thigh SS18-SSX2 * * * * 130 Synovial sarcoma-04 31 M Abdomen SS18-SSX1 * * 131 Synovial sarcoma-05 32 M Lung, met. SS18-SSX1 * * 132 Synovial sarcoma-06 63 F Lung, met. SS18-SSX1 * 133 Synovial sarcoma-07 18 F Hand SS18-SSX1 * * 134 Synovial sarcoma-08 77 F Chest wall SS18-SSX2 * * 135 Synovial sarcoma-09 13 F Shoulder SS18-SSX2 * 136 Synovial sarcoma-10 17 F Forearm SS18+ FISH * * 137 Synovial sarcoma-11 43 M Arm SS18-SSX1 * * 138 Synovial sarcoma-12 14 M Thigh SS18-SSX2 * * 139 Synovial sarcoma-13 48 F Thigh SS18-SSX1 * * 140 Synovial sarcoma-14 35 F Abdominal wall SS18-SSX2 * * 141 Synovial sarcoma-15 23 F Abdominal wall SS18-SSX1 * * 11

142 Synovial sarcoma-16 29 F Pleura SS18-SSX1 * * 143 Undifferentiated small round cell sarcoma-01 7 M Ankle - * * 144 Undifferentiated small round cell sarcoma-02 33 F Liver - * * 145 Undifferentiated small round cell sarcoma-03 10m M Mediastinum - * * FAP, familial adenomatous polyposis; NF1, neurofibromatosis type I; PM(-), negative for PAX3-MAML3; GEP, gene expression profling. IHC, immunohistochemistry. 12

Supplementary Table 3. Top 150 Overexpressed and Downregulated Genes in Biphenotypic Sinonasal Sarcoma Upregulated Genes Downregulated Genes Gene p-value Ratio Gene p-value Ratio 1 PLUNC 4.39E-17 81.859 HOXB7 1.04E-05-13.457 2 CXCL17 2.91E-08 45.462 KRT1 0.00477499-11.081 3 C20orf114 1.44E-09 43.499 HOXD13 0.00210586-10.841 4 CAPN13 5.97E-07 39.921 HOXB5 9.85E-09-10.772 5 PIGR 2.75E-07 33.284 PMP2 0.00234188-10.293 6 XAGE2B 1.72E-15 29.737 PRG4 2.46E-05-10.031 7 SERPINB3 1.39E-07 29.127 PLA2G2A 3.52E-05-9.9762 8 PCP4 1.79E-08 27.85 GABRA2 0.000338385-9.0026 9 C13orf30 5.13E-06 27.73 PCOLCE2 0.000319173-8.4021 10 CTAG1B 1.55E-05 26.232 CDH19 0.000299448-8.1449 11 GDF7 8.63E-11 24.295 ADH1B 0.0034806-7.813 12 GALNT17 6.04E-09 22.784 NKAIN2 0.00124955-7.8084 13 TEKT1 7.53E-17 22.66 CIDEC 0.000101102-7.8061 14 SCGB1A1 1.67E-06 21.586 C1orf68 0.0300937-7.2147 15 COL6A6 5.35E-08 20.168 TNMD 0.000501419-7.172 16 BMP5 3.90E-06 19.381 MLANA 0.0175587-7.048 17 PIK3C2G 7.34E-09 19.114 NPTX1 0.00118341-7.0251 18 ALX1 6.84E-05 18.932 ANK2 1.58E-10-6.9056 19 RSPO1 1.83E-07 18.625 HOXA4 2.12E-06-6.7845 20 GABBR2 7.17E-06 17.219 LAMA2 1.66E-06-6.7686 21 MUC16 2.14E-08 16.219 HOXA2 2.74E-06-6.7202 22 CYP2F1 2.88E-06 16.029 HOXB3 3.05E-05-6.6371 23 SV2C 9.73E-07 15.814 MEOX2 9.19E-05-6.5963 24 C20orf186 3.97E-06 15.505 LCE6A 0.0277075-6.4217 25 CDH8 9.01E-06 15.121 FLG2 0.0192111-6.4044 26 LCN2 4.99E-05 15.1 COMP 0.00579508-6.3749 27 C1orf194 6.41E-09 15.087 GRIN3A 0.000391851-6.3741 28 C11orf88 1.96E-06 14.117 TUBB4 0.00148051-6.3559 29 FAM3D 3.20E-05 14.06 SIM1 0.00052901-6.2702 13

30 ERN2 1.46E-06 13.388 STMN2 0.000775597-6.2318 31 TCEAL2 0.000111257 13.231 USP9Y 0.0356565-6.1897 32 ADH7 8.56E-05 13.22 TOX 0.000266356-6.1611 33 AGXT 4.62E-05 13.195 IL17B 0.00106547-6.157 34 DBX1 2.11E-08 13.16 HOXA9 3.81E-05-6.1465 35 LYPD2 9.38E-08 12.739 PKIA 6.01E-07-6.1147 36 SCGB2A1 0.000102285 12.724 POU3F2 0.000948689-6.0511 37 SEC14L3 1.27E-08 12.586 JARID1D 0.0379543-5.7507 38 MMP10 2.29E-06 12.541 TK1 0.000695896-5.7213 39 GDF10 6.14E-08 12.243 CYorf15A 0.0281793-5.7045 40 ASCL1 6.03E-06 12.179 NCAM2 0.000666985-5.7031 41 ALX4 0.000110112 12.149 SGCG 0.000288481-5.6573 42 FGFR2 1.12E-05 12.052 BHLHE22 2.07E-05-5.6341 43 CCDC37 3.90E-07 11.856 BCHE 3.33E-05-5.6156 44 C4orf49 6.32E-09 11.824 HOXB8 0.00257608-5.5134 45 DNAI1 4.08E-07 11.708 LOR 0.025267-5.4946 46 NWD1 3.93E-05 11.611 CXorf57 0.00139664-5.4886 47 MME 4.24E-07 11.406 PRL 0.00993249-5.4767 48 C10orf92 2.51E-06 11.277 CASP14 0.0156152-5.4738 49 SLPI 5.90E-05 11.188 ODZ1 0.000896747-5.4614 50 CAPZA3 2.03E-06 11.055 SCRG1 0.00913605-5.4064 51 GALNTL6 4.25E-05 11.051 CADM2 0.00493505-5.3848 52 GRP 8.90E-05 11.016 KRT2 0.0279916-5.3721 53 CCDC33 5.71E-09 11 ISG15 2.64E-06-5.3318 54 KRT19 1.34E-06 10.821 PTTG3P 0.00661097-5.3134 55 PSCA 4.86E-06 10.511 C5orf46 0.000474402-5.3109 56 CLDN3 1.32E-05 10.253 GFRA3 0.0129174-5.2934 57 FAM5C 1.16E-05 10.191 NPTX2 0.00339756-5.2744 58 TTR 1.42E-05 10.025 CYP4F22 0.00413109-5.2622 59 SPRR3 0.00644916 9.9884 LOC730833 0.0359634-5.2196 60 SLC18A2 9.60E-06 9.88 TMEFF2 0.00969879-5.2066 61 CEACAM5 0.00017398 9.8067 COL9A1 0.000603958-5.1514 62 GREM1 0.000102242 9.6702 LOC392395 0.00144798-5.1061 63 ATRNL1 1.83E-11 9.5795 CDH12 0.00715154-5.0859 14

64 KRT13 0.00190808 9.4874 HOXA13 0.0133703-5.0709 65 PCSK1N 2.61E-05 9.4343 FOXD1 0.000728918-5.0215 66 DBC1 4.56E-05 9.4102 SPRR2B 0.00976528-4.9945 67 SVOPL 3.57E-06 9.3384 CDCA7 0.00063766-4.8852 68 KRT8 1.67E-05 9.3125 SCN7A 0.00071488-4.8484 69 LRRC50 3.18E-07 9.3047 PRUNE2 0.000316209-4.8415 70 C3orf51 0.000430141 9.2921 POPDC3 0.00213165-4.8051 71 GATA2 1.17E-06 9.2514 GABRB1 0.00925977-4.8049 72 NTN5 5.20E-07 9.2453 TMEM132D 0.0189635-4.8014 73 ALX1 3.59E-05 9.1691 PGBD5 0.00262015-4.7903 74 WDR38 4.24E-12 9.1217 MOXD1 1.71E-06-4.7423 75 PAX1 1.46E-07 9.0333 FLG 0.0933306-4.733 76 FMO1 1.15E-05 8.9895 LCE2B 0.0464016-4.7102 77 DNAH2 1.49E-05 8.9859 SALL3 0.0022649-4.7054 78 CEACAM6 0.00404314 8.9042 RXRG 0.000835452-4.6578 79 LOC653216 8.18E-13 8.8905 CAMK2N2 0.000430515-4.6299 80 MIR1251 0.00103899 8.879 TRPC3 0.00130805-4.6296 81 NTRK3 1.02E-06 8.8224 ANGPTL5 0.00192239-4.6119 82 SHD 0.00063655 8.8138 SOX6 7.71E-07-4.6074 83 ALX3 1.82E-10 8.8001 TCBA1 0.00427285-4.5569 84 GABRP 0.000132833 8.7754 SPRR2E 0.101103-4.5497 85 UBL4B 0.000124852 8.5023 PLSCR2 0.0183303-4.5219 86 SLC27A6 6.00E-10 8.4982 TYRP1 0.0293822-4.5195 87 XAGE2 4.36E-12 8.4938 SCGB2A2 0.0207824-4.5057 88 ADD2 3.72E-11 8.4592 LIN28B 0.0478772-4.4671 89 SFRP2 0.000249023 8.4413 DSC1 0.0320409-4.4613 90 PTH2R 7.60E-05 8.4316 PNMA2 0.00301205-4.4505 91 MSLN 6.30E-05 8.4251 NELL1 0.0484135-4.4146 92 AGR3 2.57E-08 8.3564 RGPD1 0.0109749-4.377 93 PPP1R1A 5.74E-06 8.2719 TMEM195 0.00069676-4.3536 94 C20orf85 1.54E-08 8.2506 KIF1A 0.0120386-4.3452 95 FOXA1 0.000116756 8.2475 PDZRN4 0.00105691-4.3433 96 PAX3 7.29E-05 8.2211 OGN 0.00101552-4.3408 97 AGR2 7.77E-05 8.2086 CHGA 0.00613909-4.326 15

98 CCKAR 4.71E-05 8.2013 HOXA5 0.000368769-4.323 99 TCN1 0.000112729 8.1742 HOXB4 0.000147181-4.3164 100 SERPINB11 3.63E-05 8.1582 SLC7A10 0.000569256-4.3011 101 ENKUR 3.48E-05 8.0988 LOC645993 0.0150569-4.2949 102 POU4F1 0.000853803 8.0529 LPPR5 0.000588422-4.2883 103 POU3F3 7.51E-05 7.9827 BIRC7 0.00232648-4.2759 104 NEUROG2 0.000264238 7.9305 WIT-1 0.00692671-4.2425 105 RASL10B 7.45E-06 7.9278 COL20A1 0.00345151-4.2269 106 VTCN1 0.000979247 7.9278 PCSK1 0.00309818-4.2073 107 C10orf81 0.000556033 7.7769 KRTAP4-7 0.0759449-4.1958 108 MYOCD 0.000206078 7.663 DCT 0.0147734-4.1955 109 EYA1 0.00100156 7.6549 KRT77 0.0324527-4.1893 110 PTPRT 0.000130063 7.6477 PBK 0.0184913-4.1657 111 IL33 1.32E-10 7.6339 RDH12 0.00924201-4.1431 112 C1orf110 0.000346133 7.6184 PKD1L2 0.000465405-4.1373 113 RSPH1 6.02E-08 7.5733 HAS1 0.0108455-4.1341 114 GSTA1 0.000597503 7.5395 DCX 0.010975-4.103 115 TTLL10 0.000313309 7.526 LCE2A 0.0494144-4.1013 116 VSTM2A 1.28E-05 7.5216 HOXA7 0.000450772-4.0897 117 ALDH1A2 1.92E-06 7.4885 HOXA10 9.54E-05-4.088 118 SLC6A14 3.28E-05 7.4712 LYG2 0.00142611-4.0822 119 C1orf92 8.40E-07 7.4203 HOXA11 0.0181798-4.0822 120 EYA4 0.000101901 7.3837 PASD1 0.017145-4.0743 121 ADRA2C 4.04E-08 7.3544 CSRP3 0.0397223-4.0413 122 MYOD1 0.00338096 7.3498 CST6 0.0350487-4.0375 123 NOS1 0.00196216 7.3307 IGSF1 0.00020312-4.0368 124 SLC27A2 8.86E-09 7.2862 KRT27 0.0640569-4.0353 125 MIR1295 7.10E-07 7.2837 NDST4 0.00282094-4.0171 126 CES4 3.79E-05 7.2016 FABP3 3.54E-05-4.0033 127 SPTB 1.34E-06 6.9061 TMEM16D 0.00837574-3.9957 128 C1orf87 9.81E-07 6.8446 IL1F10 0.020815-3.973 129 ADRA2A 2.57E-06 6.7533 CHRDL2 0.0162398-3.9533 130 LRRC26 0.00115479 6.7452 TOP2A 0.00902653-3.9523 131 SEC1 2.75E-05 6.7322 ADIPOQ 0.0169976-3.9467 16

132 KRT6A 0.0274447 6.7121 PSAT1 0.000145387-3.9405 133 PAX2 0.000700939 6.6691 DSG1 0.0303598-3.932 134 ELF5 0.000124623 6.6192 EBF2 0.00711868-3.9296 135 ALDH3A1 0.00132063 6.5814 BVES 8.11E-05-3.9225 136 USP6 4.71E-05 6.5363 NOG 0.0077547-3.9156 137 MSMB 4.78E-05 6.5217 EDN3 0.0219593-3.9062 138 FOXJ1 6.43E-06 6.5162 LCE2D 0.0183431-3.9019 139 CYP4B1 0.00111263 6.4792 PCDH10 0.00446531-3.8997 140 ACADL 3.41E-05 6.364 ZFY 0.0422992-3.8948 141 PNLDC1 0.000167751 6.3437 LCE1C 0.0340865-3.8933 142 SH3GL3 0.00441108 6.3172 RASGEF1C 0.00635796-3.8874 143 CHRNA6 3.30E-09 6.315 COL25A1 0.000995746-3.8742 144 C20orf185 6.11E-05 6.2814 LZTS1 0.0198336-3.8675 145 FGF9 0.00551208 6.2442 CDCA2 0.000986709-3.8651 146 CA11 0.000439906 6.2398 SERPINA12 0.0259683-3.8623 147 ARSI 1.81E-05 6.1973 CDCA5 0.00765013-3.8621 148 NOV 0.000103639 6.1854 UBE2T 0.00265316-3.8567 149 NCRNA00113 1.08E-10 6.1756 MFAP5 0.00465583-3.8433 150 CYP2B7P1 0.00240509 6.1601 SLN 0.0180046-3.8399 Note. Genes in boxes (n=6) had their overexpressions confirmed by qpcr and immunohistochemistry, genes in bold (n=4) had their expressions confirmed by qpcr. 17

Supplementary Table 4. Top 500 Differentially Expressed Genes Between Biphenotypic Sinonasal Sarcoma and Alveolar Rhabdomyosarcoma*^ Upregulated Genes in SNS Downregulated Genes in SNS Gene p-value Ratio Gene p-value Ratio 1 PLUNC 7.07E-09 108.107 TMEM132D 0.000246646-126.97 2 SERPINB3 9.40E-06 89.7604 FGF8 0.00012864-71.772 3 C13orf30 0.00126438 73.0828 SMYD1 0.00608899-71.181 4 CTAG1B 0.00198819 53.4672 ELA2A 0.000555404-62.578 5 C20orf114 4.42E-05 48.4547 DCX 0.00014379-62.026 6 GDF7 5.65E-05 38.466 APOBEC2 0.00135815-61.169 7 C11orf88 0.00176701 32.9217 NELL1 0.00026629-60.501 8 SV2C 0.000834003 32.125 GATA4 0.00102645-60.098 9 SYT1 0.00585911 31.9214 NRTN 0.00142368-57.791 10 PIGR 0.0213863 30.7632 ACTA1 0.00854447-56.84 11 XAGE2B 4.27E-06 29.8136 ACTC1 0.00651005-54.811 12 TEKT1 1.71E-06 29.4818 MTMR7 8.58E-05-53.976 13 CXCL17 0.0224302 28.3944 FBN3 0.000943276-51.435 14 CAPN13 0.0194503 27.711 MYH8 0.00497254-50.996 15 SLC18A2 0.00183949 27.2424 C20orf200 0.000132883-48.776 16 SELV 0.0210812 25.6551 KBTBD5 0.0038156-48.748 17 PIK3C2G 5.73E-05 25.0835 MYO18B 0.0062162-45.226 18 ADAM33 0.000167624 25.0491 FRMPD1 0.005357-42.466 19 RSPO1 0.0157468 23.9273 TAGLN3 0.00257936-41.499 20 CAPZA3 0.000974623 22.7997 MIMT1 1.73E-05-39.489 21 NOV 0.000877829 20.6772 POPDC3 9.56E-06-38.625 22 TFAP2C 0.000543876 20.6478 RGR 5.65E-05-38.551 23 MYOCD 0.00757379 19.5847 SRRM4 0.00127988-37.947 24 SH3GL3 0.0259415 19.4634 EDN3 0.00115999-37.229 25 ENKUR 0.00142368 19.3349 LOC392395 0.000420696-36.469 26 RSPH1 0.00014379 19.322 C1orf105 8.05E-06-35.383 27 NEGR1 0.00374303 19.2725 PGBD5 6.87E-05-35.27 28 GALNT17 0.00368471 19.2129 OLIG2 5.73E-05-35.25 29 TTR 0.0154405 19.0238 IL17B 0.00374303-35.013 18

30 ALX4 0.00714315 18.7512 NGB 3.13E-05-34.292 31 GPR81 0.00242539 18.6282 SALL3 0.00118474-34.208 32 MME 0.00521344 17.6025 CKM 0.0494447-32.234 33 SOX2 0.00341445 16.7433 PBK 0.00416909-30.095 34 CES4 0.00375068 16.71 PRDM12 0.00183949-29.685 35 ZIC2 0.0169789 16.1202 CHRNG 8.05E-06-29.021 36 RSPO3 0.000275236 15.5202 DUSP26 0.0184903-28.574 37 C20orf186 0.0552092 15.3705 SLC18A1 7.07E-09-27.992 38 CCKAR 0.0455091 15.2583 TRIM55 1.23E-05-27.817 39 KNDC1 0.00890939 15.1827 CHRND 1.07E-05-27.123 40 PRAME 0.0679781 15.0846 BTBD17 0.00530106-26.065 41 PAX9 0.0049782 14.6384 POU4F2 0.00758612-25.846 42 SVOPL 0.0130128 14.5803 CADM2 0.00445602-25.5 43 DLX6AS 0.0451356 14.543 FGFR4 4.27E-06-25.496 44 FAT4 7.63E-06 14.3826 LZTS1 0.00963682-25.196 45 C1orf194 0.0137725 14.2848 CDH12 0.00981869-25.159 46 COL6A6 0.0208391 14.127 MYT1L 0.000529863-25.085 47 FAM5C 0.012062 13.9021 MYOG 1.17E-06-24.532 48 CCDC37 0.0036847 13.7031 DES 0.00925934-23.657 49 MSLN 0.0212893 13.6539 CAPN6 8.44E-05-23.144 50 PTH2R 0.0222658 13.6487 LOC389827 9.56E-06-23.13 51 MMP2 3.29E-06 13.6071 UTS2R 3.54E-06-22.673 52 SNORD94 0.00789484 13.5301 ZSCAN10 0.00266213-22.571 53 ALS2CR11 0.000187836 13.4002 SMPX 0.00239303-22.557 54 C10orf92 0.0194032 13.2028 GPR123 0.000448061-22.322 55 HLA-DRB4 0.0727773 13.1396 DLGAP2 0.000234024-21.85 56 C4orf49 0.000275236 13.0326 MYOM3 0.0100102-21.548 57 GABBR2 0.0321504 12.9927 CBLN2 0.0011904-21.435 58 DNAH12L 0.0111607 12.9609 C10orf71 0.000148141-21.199 59 CYP2F1 0.0404757 12.907 SBK2 0.0104548-20.672 60 AOX1 0.0145664 12.8354 SYN2 1.80E-07-20.576 61 WDR38 0.00014379 12.743 TCF15 0.00509999-20.558 62 PCSK1N 0.0225447 12.6568 MYO7B 0.00558443-20.274 63 CCDC33 0.0038156 12.6436 INA 0.0134378-20.204 19

64 CYP4B1 0.0359645 12.5494 CSRP3 0.0719089-20.08 65 DUOXA1 0.00527865 12.3579 SOX3 0.000545795-19.799 66 CH25H 0.00106493 12.2933 FAM64A 0.000375799-19.646 67 C1orf192 0.000152943 12.2791 ELA3A 0.00108602-19.087 68 OR2M4 0.0242465 12.1157 KREMEN2 3.82E-05-19.033 69 UBL4B 0.0356771 11.6376 CHGA 0.0251995-19.002 70 LOC10019237 0.00393566 11.4584 PKP1 0.000981495-18.759 71 GDF10 0.000246646 11.4269 LHX1 0.000965818-18.516 72 VIT 0.0407127 11.3238 AURKA 0.00128496-18.423 73 NTNG1 0.0219137 11.3131 ARPP-21 9.61E-05-18.385 74 C9orf4 0.0340917 11.2538 TTN 0.00758612-18.315 75 GRP 0.0352728 11.1353 FAM181A 0.0473495-18.256 76 KRT6A 0.168091 11.0223 PLEKHG4B 0.0053033-18.183 77 HLA-DRB5 0.246056 10.8967 TMSB15A 0.0172877-18.127 78 C20orf85 0.000391551 10.8852 MYLK4 0.00015506-18.075 79 POU3F3 0.0625721 10.8794 SYT4 0.0440483-18.009 80 SERPINB13 0.125638 10.8078 CENPF 0.00698151-17.909 81 PTHLH 0.000463653 10.805 AURKB 0.0100779-17.849 82 CPZ 0.00557187 10.736 PKD2L1 0.00552198-17.814 83 LOC653216 0.000406635 10.7068 MYL4 1.71E-06-17.674 84 ELF5 0.0407127 10.6834 KIFC1 0.00629182-17.479 85 CYS1 0.0122425 10.5882 ZNF488 0.00197293-17.42 86 WIF1 0.0442668 10.5657 MCM2 0.00253985-17.395 87 COLEC12 0.00155659 10.5555 MYH13 0.00474972-17.303 88 TBX3 5.24E-06 10.4762 MIR1289-2 0.017965-17.294 89 C4orf7 0.208044 10.462 MYBPHL 0.0198512-17.267 90 RGS22 0.00520946 10.434 MYH7 0.195376-17.123 91 CP 0.0110733 10.4217 SEZ6 0.00527751-16.998 92 C22orf15 0.0100839 10.4183 CDCA5 0.00245785-16.797 93 COL27A1 0.005357 10.4163 MICAL2 8.05E-06-16.784 94 SCNN1A 0.0241351 10.4145 TNNT3 0.00492918-16.774 95 HPGD 0.0382202 10.382 MYLK2 0.000584416-16.754 96 CYP2B7P1 0.0635272 10.3634 SRPK3 0.0159336-16.559 97 DNAH2 0.00272058 10.3607 CDC45L 0.00238913-16.291 20

98 SCGB2A1 0.0944868 10.309 CNR1 3.48E-05-16.222 99 CCDC114 0.00683178 10.2613 SLN 0.0077061-16.184 100 SNORD9 0.0233387 10.2228 MYLPF 0.0834328-16.18 101 MIR874 0.079235 10.136 BEST3 0.0429649-15.901 102 RARG 0.00698151 10.1261 CST2 0.0116279-15.885 103 MXRA8 0.000743037 10.1071 PLCXD3 0.00314084-15.785 104 CEACAM6 0.102294 10.0707 CXorf57 0.0111389-15.679 105 XAGE2 0.000758485 10.0611 LHX4 0.00266213-15.517 106 DNAH3 0.0278656 10.0135 MYL2 0.107952-15.514 107 CYP2A13 0.0106887 9.99812 TROAP 0.00781324-15.504 108 ZIC5 0.0816127 9.9956 PRL 0.0813648-15.485 109 IL33 0.000298164 9.70844 NEUROD2 0.000493172-15 110 GREM2 0.102294 9.56181 CACNG1 0.00331608-14.951 111 OR2M5 0.0473495 9.50801 TEX14 0.00667065-14.823 112 KRT23 0.0965258 9.46753 MYBPH 0.0406591-14.808 113 PSCA 0.0483224 9.43129 FCRLA 0.0351634-14.753 114 BMPER 0.0155432 9.38904 TOP2A 0.0144286-14.748 115 C1QTNF4 0.0149345 9.38813 LIPG 0.00202647-14.641 116 GALNTL6 0.0215319 9.35152 SNTG1 0.0294247-14.626 117 ARSI 0.00248247 9.34971 GTSE1 0.0177741-14.614 118 LEPR 5.24E-06 9.32462 PTTG3P 0.0251995-14.463 119 LMOD1 0.000920138 9.26316 LOC100133545 0.0039169-14.301 120 IGFL2 0.00620245 9.20796 GRM3 0.0158752-14.234 121 FAM181B 0.00931155 9.1858 PKIA 6.69E-05-14.17 122 NKX6-1 0.017965 9.17839 INSM1 8.05E-06-13.959 123 SLC14A1 0.0120158 9.17671 KCNT1 0.0284401-13.946 124 AKAP14 0.0105014 9.16511 BHLHE22 0.00183949-13.907 125 SNORA74A 0.0214982 9.10094 RGPD1 0.0628256-13.816 126 ERN2 0.0472177 9.09972 CDH3 0.0220369-13.707 127 KRT6B 0.269951 9.09223 MYO16 0.0147057-13.677 128 CART1 0.162602 9.06195 C20orf166 0.1001-13.339 129 FADS2 0.00890939 9.03545 CPA5 8.58E-05-13.338 130 TAS1R1 0.0139419 9.03176 KRT33B 0.0282435-13.336 131 C10orf93 0.00601277 9.02984 SGCG 0.00777897-13.244 21

132 GSTA1 0.127253 8.99287 CCNB2 0.0108065-13.158 133 ADD2 0.00194429 8.91681 PROX1 0.000257545-13.039 134 GABRP 0.0816098 8.85985 SMTNL2 0.00444127-12.733 135 MUC16 0.0392326 8.81608 LOC100128675 0.000482203-12.396 136 C21orf130 0.00115916 8.79975 BUB1 0.0102376-12.371 137 C1orf158 0.0498391 8.64568 TNNC1 0.081791-12.368 138 AGR3 0.0044149 8.60449 PITX3 0.000235586-12.196 139 CEACAM5 0.110621 8.60244 CABP7 5.24E-06-12.167 140 VWA3B 0.00887671 8.54641 SIM1 0.0189609-12.125 141 CHD5 0.0065092 8.53991 DTL 0.00757141-12.071 142 FOXL2 0.0258602 8.52046 CDCA7 0.010396-12.039 143 KRT19 0.0588622 8.4771 DBH 0.0404757-12.009 144 CD200 0.00169042 8.45454 C2orf48 0.0201784-11.993 145 C1orf87 0.00489321 8.41708 SCN4A 0.0147946-11.833 146 TACSTD1 0.0377883 8.39666 KIF1A 0.102294-11.806 147 FAM3D 0.139077 8.3849 TRIM36 0.00168828-11.797 148 PANX2 0.0204284 8.31392 ASPM 0.00870422-11.795 149 C11orf92 0.0526495 8.29751 MYLC2PL 0.0051167-11.785 150 AMTN 0.0513004 8.25237 MGC45800 0.0159734-11.676 151 LYPD2 0.0136607 8.23864 NKAIN4 0.0339158-11.559 152 FOXG1 0.0250166 8.21989 CAMK2B 0.000379559-11.519 153 KLK11 0.162501 8.20454 KIF20A 0.0190618-11.505 154 ODAM 0.20942 8.14329 HSPB3 0.00238913-11.469 155 OPRK1 0.0167622 8.13192 DNAH17 0.0105217-11.421 156 VSTM2A 0.0349503 8.07592 STMN2 0.0121886-11.381 157 KCNN1 0.0145635 8.06143 HRASLS 0.0206304-11.315 158 ARMC3 0.0272916 8.04674 ISG15 0.00499736-11.28 159 CYP1A2 0.0590961 7.99739 KIF19 3.29E-06-11.239 160 PNMA3 0.00374303 7.98842 CHRDL2 0.0191143-11.239 161 SEMA6D 0.00119042 7.96599 TNNI1 0.01663-11.159 162 S1PR2 0.00183949 7.9479 NCAPG 0.00475844-11.156 163 FLJ23834 0.0404757 7.93687 FAM163A 0.0985109-11.135 164 SCUBE3 0.127628 7.92442 LOC389257 0.020474-11.114 165 CD164L2 0.167554 7.90832 BVES 9.09E-05-11.092 22

166 FLJ10324 0.00915346 7.90172 KRT31 0.00331742-11.081 167 NTRK2 0.000463653 7.86606 KIF24 0.0134927-11.078 168 MMP10 0.0567918 7.85082 LINGO1 0.0206628-11.042 169 ESPN 0.0523775 7.84315 OTOF 0.00140168-11.038 170 NKD1 0.0867874 7.83536 SCN3B 0.00450465-10.944 171 ENPP2 8.05E-06 7.82768 EPHA7 0.0245423-10.895 172 ABCA13 0.0721518 7.75098 ARSF 0.0098606-10.884 173 C1orf92 0.00702106 7.73309 SYT17 0.0225447-10.848 174 LCN2 0.15499 7.71067 MYT1 0.0659801-10.814 175 HPSE2 0.0442654 7.69215 COL25A1 0.00393137-10.81 176 FOXJ1 0.0106302 7.68721 NKAIN1 0.00203338-10.767 177 CCL28 0.000448886 7.65782 C16orf59 0.0930286-10.76 178 ADRA1D 0.0659801 7.65618 ESCO2 0.00759177-10.733 179 SLC6A14 0.0621268 7.64271 HOXD13 0.19704-10.721 180 SNORA60 0.00847146 7.63817 KCNH2 6.06E-05-10.717 181 ALX3 0.000207579 7.61932 MYBPC2 0.0200964-10.68 182 SEC14L3 0.0490796 7.59649 UNC45B 0.0215873-10.651 183 WNT5A 0.0195874 7.52609 TK1 0.0137071-10.589 184 SERPINB11 0.0843453 7.49965 PNMA2 0.0468203-10.559 185 KRT5 0.295017 7.45923 HIST1H1B 0.00510218-10.53 186 WNT7B 0.0576228 7.44624 PCDH8 0.000780778-10.468 187 LOC730347 0.0365952 7.41223 INHBE 6.51E-05-10.438 188 PTPN13 0.00956912 7.36979 LBX1 0.0679781-10.422 189 ZFHX4 0.000246646 7.33829 LOC340156 0.000180339-10.352 190 ASCL1 0.0986927 7.31928 ENPP6 0.0378502-10.343 191 STOML3 0.0392326 7.30737 SPSB4 5.24E-06-10.339 192 TWIST1 0.0149408 7.26853 KIF4A 0.058834-10.294 193 PNLDC1 0.0553282 7.26826 ANKRD2 0.0168016-10.279 194 CNTN1 0.0562559 7.26157 LOC154822 5.24E-06-10.241 195 OR2T4 0.0684334 7.23925 MIR660 0.00255472-10.166 196 DYNLRB2 0.0168241 7.22726 AIPL1 1.86E-06-10.011 197 DLX5 0.0251995 7.20993 KCNF1 0.029823-9.9969 198 WNK4 0.113487 7.17952 SGOL1 0.0113204-9.9688 199 GLIS1 0.0634845 7.17813 SST 0.0479032-9.9621 23

200 LLGL2 0.0308545 7.17112 ACTN2 0.0591877-9.9529 201 DUOX1 0.00792649 7.15229 CCNE1 0.000957315-9.9374 202 SLC6A4 0.0142732 7.14847 MPO 1.33E-05-9.8765 203 EPHA5 0.0281748 7.12519 ASB10 0.0323086-9.864 204 CCL14 0.00183949 7.07469 HJURP 0.00890939-9.837 205 C6 0.114154 7.07217 GJD4 6.30E-06-9.6348 206 SNORA39 0.00399848 7.05972 RAPSN 2.92E-05-9.6348 207 FOXA1 0.165607 7.05048 COL22A1 0.0983549-9.6322 208 ABCG2 0.00712692 6.97008 COMP 0.032158-9.592 209 MIR27B 0.0198267 6.96941 RHEBL1 0.000493172-9.567 210 C10orf79 0.00375068 6.9337 NHLH1 0.00781324-9.55 211 KRT14 0.275883 6.90906 NKX6-2 0.0124246-9.5469 212 PAX3 0.0756772 6.90061 LRTM1 0.021265-9.5443 213 ALX1 0.0843453 6.85754 LPPR5 0.0118675-9.5178 214 CYTL1 0.0288208 6.84044 DRGX 0.000119658-9.4566 215 LPPR3 0.031246 6.83028 BLM 0.00193701-9.4355 216 DPYS 0.0495627 6.82347 LOC727924 0.170194-9.4238 217 ADAM28 0.00586097 6.81877 C14orf73 0.00313586-9.4204 218 GPX6 0.111356 6.81122 LAMA1 0.0362659-9.4117 219 HOXC10 0.281157 6.80079 MEOX2 0.00623485-9.3611 220 RNF175 0.020904 6.78131 CASQ2 0.00762922-9.3584 221 ANXA8L1 0.283314 6.76991 C13orf33 0.000301003-9.3566 222 PLCH1 0.0378502 6.76351 UBE2T 0.0108338-9.2911 223 CDC42BPG 0.0364579 6.7518 PRKAG3 0.00829392-9.2794 224 C4orf45 0.0033334 6.7035 NES 0.0147946-9.2168 225 C3orf15 0.0508328 6.67439 HAMP 0.0595948-9.166 226 NUDT9P1 0.0120158 6.66036 KIF18A 0.00198569-9.1446 227 C6orf97 0.0200964 6.63768 TMEM132B 0.00769702-9.1389 228 DNAI1 0.0587692 6.62857 PASD1 0.112886-9.1258 229 LRRC50 0.0679781 6.62606 CA9 0.0288256-9.1088 230 LDLRAD1 0.00331608 6.61087 KIAA0367 0.095085-9.1087 231 ASTN1 0.0659824 6.60173 TFRC 0.0716598-9.1024 232 GAL3ST3 0.191014 6.5891 HFE2 0.0845411-9.0816 233 NWD1 0.117204 6.57299 FIT1 4.79E-06-9.0592 24

234 TC2N 0.0420109 6.56477 IGF2BP3 0.011321-9.0567 235 ADH7 0.282893 6.56298 ZNF311 0.0144641-9.0204 236 MIR1295 0.0233387 6.54327 HRNBP3 0.0213831-8.9828 237 SERPINB4 0.0346129 6.49628 FANCI 0.011321-8.9738 238 CA11 0.0038127 6.48975 MIR133B 0.0150416-8.9539 239 CLDN3 0.0536166 6.48853 KLHL30 0.00527865-8.93 240 LONRF2 0.000854104 6.46795 PEG3 0.0106302-8.8872 241 ATRNL1 0.00665536 6.46305 PEG3AS 1.51E-06-8.8834 242 HORMAD1 0.0100548 6.44928 C13orf3 0.0105221-8.818 243 SNORD90 0.00267054 6.44769 BRSK2 0.000276319-8.788 244 SCGB1A1 0.118601 6.44605 MYL1 0.127654-8.7858 245 SOX21 0.224357 6.44438 ATPGD1 0.0262322-8.7644 246 OR2M3 0.00585448 6.43241 RRP12 0.0763883-8.7635 247 TMPRSS11E2 0.248062 6.43126 KBTBD10 0.0162198-8.7365 248 PTX3 0.0482249 6.41336 NEU4 0.101233-8.6578 249 TTLL10 0.128323 6.37731 STAC3 0.00202498-8.6454 250 TRPM3 0.0320107 6.33847 PPM1E 0.0619712-8.6037 251 MIR125A 0.0662151 6.32487 CENPE 0.00775127-8.5688 252 CCL16 0.000152492 6.30745 INSM2 0.0424381-8.5515 253 WDR86 0.0233387 6.29005 KCNJ5 0.0015469-8.5268 254 CCDC85A 0.00176701 6.27166 KIF11 0.00129353-8.4913 255 B3GNT7 0.045377 6.25137 ANK2 0.000101895-8.4676 256 TMEM215 0.0494447 6.23281 PIPOX 0.0320107-8.4655 257 XG 0.0100102 6.23017 C5orf46 0.0127254-8.4589 258 VEGFC 0.000207579 6.22669 C7orf33 0.0244215-8.4362 259 SLPI 0.0951938 6.2248 BIRC5 0.0178478-8.4329 260 PPP1R1A 0.0659233 6.21106 ZNF695 0.0472121-8.4207 261 UGT2A2 0.13259 6.20645 DDN 0.0166762-8.4038 262 RARB 0.000101895 6.19518 ESRRG 0.00109444-8.3403 263 LRRC26 0.0793988 6.18337 CTNND2 0.00377321-8.3273 264 C11orf21 0.0166539 6.18272 SCT 9.61E-05-8.2848 265 VWA3A 0.0088291 6.18117 ALK 0.00194429-8.272 266 LRRTM4 0.266407 6.17728 N4BP3 0.00446187-8.265 267 GAGE5 0.0234888 6.17674 NPPA 0.0144535-8.2539 25

268 C21orf121 0.115322 6.17348 HRC 0.0207534-8.2492 269 MIRLET7I 0.00197293 6.16919 VGLL2 0.00445602-8.2433 270 SHANK1 0.0456715 6.16681 KIR3DS1 0.0162789-8.2131 271 GPR27 0.155455 6.13313 SOX11 0.061711-8.1665 272 PAX1 0.0213344 6.13058 CRMP1 0.00743473-8.1603 273 B3GNT9 0.0100102 6.09439 C12orf48 0.0200744-8.1502 274 C1QTNF7 0.0200964 6.09214 ANKRD34B 8.96E-05-8.119 275 GAGE7 0.0200964 6.08567 C1orf135 0.0133559-8.1177 276 B4GALNT4 0.076998 6.07041 MYPN 0.0323886-8.1086 277 FGL1 0.0678679 6.06303 SGCA 0.0309974-8.0975 278 SLC27A2 0.0133559 6.06159 CSMD1 0.0331962-8.0795 279 GRIA3 0.00610532 6.05702 SNTG2 0.217847-8.0436 280 NCRNA00113 0.00299344 6.03884 NXPH2 0.0873093-8.0435 281 BMP6 0.00147047 6.03475 DPP6 0.196031-8.0264 282 SNORD101 0.0682052 6.0003 ELAVL2 0.0639623-7.9749 283 XYLT1 0.0316513 5.98629 SLC26A4 0.0679781-7.9601 284 FAM183A 0.0325667 5.93913 TMEM169 0.00238648-7.9581 285 CTTNBP2 0.0043604 5.93666 EFCBP1 0.120173-7.8938 286 ROPN1L 0.0233387 5.9356 CYP27B1 0.0400638-7.8696 287 TSPAN10 0.0382885 5.92905 SPINT2 0.0662291-7.8661 288 GATA2 0.00692588 5.91366 EPHA8 0.0260871-7.8561 289 TSPAN32 0.0242465 5.91246 COL20A1 0.115076-7.8198 290 ARSE 0.243208 5.89675 GP6 0.0404757-7.797 291 SNORD36B 0.0733641 5.88282 RPL3L 0.0366279-7.7549 292 SNORA13 0.0240736 5.86938 OTX2 0.0131615-7.7508 293 TCN1 0.239387 5.85955 C15orf42 0.0276071-7.7466 294 OR2A7 0.0454479 5.85948 COL9A1 0.0233387-7.7389 295 AQP5 0.132235 5.85309 CKAP2L 0.0462567-7.719 296 C20orf185 0.185747 5.83802 KCNG3 0.00270741-7.7143 297 LRRC4B 0.0561263 5.83302 MLF1IP 0.00781324-7.6489 298 GDNF 0.00789484 5.81647 TSG1 0.031887-7.6398 299 COL24A1 0.0363368 5.81264 MCM10 0.0359767-7.6121 300 ALDH1A2 0.00870422 5.80425 MYBPC1 0.112886-7.5854 301 NME5 0.043135 5.79482 OIP5 0.00299252-7.581 26

302 BIK 0.0641618 5.78207 PLSCR2 0.087016-7.5528 303 SNORA31 0.0700678 5.77463 CHRNA1 0.0522476-7.5276 304 ZP2 0.105889 5.77391 HMP19 0.00216391-7.5237 305 SNORD83A 0.0930135 5.76064 GPRIN1 0.0681369-7.5214 306 TMEM200B 0.00266977 5.74694 C6orf142 0.0827447-7.5166 307 LTF 0.153197 5.74169 ASF1B 0.00368471-7.4778 308 ADH1C 0.126829 5.73791 GINS4 0.0213344-7.4472 309 COLEC10 0.118891 5.73315 LMNB2 0.0263143-7.4177 310 YSK4 0.0316033 5.72405 RIPPLY1 0.0136273-7.4045 311 GULP1 0.00871132 5.67818 DEPDC1B 0.00276202-7.3832 312 ENPP3 0.0196911 5.67457 CTRC 0.00704223-7.3774 313 MIR24-1 0.0111389 5.66198 LRRC14B 0.00930227-7.3374 314 EFNA5 0.0793988 5.65009 MAPK8IP1 0.0284428-7.3187 315 SNORA27 0.0400638 5.64439 RGAG1 0.0259746-7.2918 316 UGT1A6 0.129194 5.64216 CACNG2 0.0395616-7.2891 317 LRP2 0.196652 5.64063 TRPM8 0.0104678-7.2562 318 SLC25A27 0.0121995 5.63597 KIF2C 0.0219952-7.2525 319 LOC401720 0.00627788 5.63575 GMNN 0.0147946-7.2444 320 FLRT2 0.00246561 5.63185 KCNC2 0.051698-7.2331 321 CNTNAP4 0.0703603 5.63037 TOX 0.0562559-7.2075 322 LOC126075 0.0347866 5.6223 TRIM72 0.000517317-7.198 323 FRMPD2 0.0247575 5.61821 PLA2G2A 0.095526-7.1587 324 EPHX2 0.0469293 5.61453 FAM65B 0.000771667-7.1128 325 GPR109A 0.0283557 5.58363 PBX4 0.0033334-7.1049 326 PITPNC1 2.70E-05 5.57999 PCOLCE2 0.104203-7.0804 327 CCDC11 0.0349543 5.57726 ABLIM3 0.00282798-7.0711 328 ALOX12P2 0.0965913 5.56673 SEMA5B 0.00204674-7.0476 329 GRIK2 0.0562559 5.56364 ST8SIA2 0.0827801-7.036 330 C15orf51 0.00446187 5.55825 NEB 0.0498465-7.0288 331 C1orf133 0.0793988 5.54405 SIRT4 0.0278656-6.998 332 PTGER3 0.0189517 5.52556 GRIN3A 0.0611808-6.9594 333 MYCBPAP 0.00238913 5.49525 CENPN 0.0759485-6.9565 334 LRRIQ4 0.0626705 5.49233 ADAMTS14 0.039212-6.9344 335 MIR429 0.0498447 5.46942 LRFN4 0.0234963-6.934 27

336 BNC2 0.0113103 5.44902 CBLN1 0.0276071-6.9183 337 HOTAIR 0.382969 5.44112 GSG2 0.102294-6.9078 338 PTPN20A 0.0992135 5.43322 PDLIM4 0.0428732-6.9055 339 RNF180 0.0566172 5.43126 PSAT1 0.0390778-6.9005 340 MMP19 0.00945099 5.41387 SLC29A2 0.00704223-6.8966 341 CDH29 0.108911 5.40366 LCNL1 0.0259746-6.8898 342 YBX2 0.0325667 5.38462 POLQ 0.00314466-6.8779 343 TUBA4 0.075974 5.37592 RBM24 0.000743037-6.8766 344 RADIL 0.0765388 5.34788 NTRK1 0.0416382-6.8722 345 TP53TG3 0.0819454 5.3421 CHEK1 0.00109272-6.869 346 CACNA1C 0.00156123 5.33591 GABRR1 0.132619-6.8685 347 DKFZP564J10 0.0547754 5.32173 CENPA 0.00693492-6.8403 348 RBMS3 1.73E-05 5.31971 ST6GAL2 0.130992-6.839 349 CYP26A1 0.0858287 5.30706 NGFR 0.000623441-6.8262 350 CLSTN3 0.00564259 5.28874 MIR30C2 0.0246205-6.807 351 MMP7 0.0914868 5.2877 FOXA2 0.162-6.7873 352 ABHD12B 0.115908 5.28765 CEP55 0.0371909-6.7815 353 NEK5 0.151488 5.28453 MELK 0.00587413-6.7316 354 LOC340508 0.128279 5.27065 EXO1 0.0142177-6.7029 355 FBLN5 0.00054426 5.26933 P2RX1 0.0595421-6.6885 356 WNT9B 0.012858 5.26647 KIF18B 0.113886-6.6867 357 TMEM204 0.000261274 5.2536 HOXB7 0.130207-6.6514 358 ANXA8L2 0.239541 5.24626 SKA1 0.000610756-6.6504 359 SNORD61 0.0718544 5.23628 XRCC3 0.00702893-6.649 360 SPINT1 0.0477028 5.22484 FOXM1 0.0493867-6.6483 361 SNORD124 0.0469807 5.22175 FRMD3 0.0319828-6.6396 362 SNORA32 0.0158752 5.22166 TACC3 0.0735034-6.6386 363 AGAP11 0.00356317 5.21766 RECQL4 0.0183482-6.6226 364 MAML3 0.00604986 5.215 SLC1A7 0.0512636-6.6138 365 TMEM37 0.019229 5.20847 C9orf61 0.0486047-6.6007 366 SNORD123 0.0284673 5.19854 TTF2 0.0452165-6.6002 367 IQSEC2 0.00203697 5.19115 CDC25A 0.0402258-6.5981 368 FER1L6 0.0827801 5.18922 SLITRK1 0.0575423-6.597 369 AGR2 0.142191 5.17903 FAM89A 0.000288886-6.5914 28

370 ODZ2 0.0441708 5.17424 CPA1 0.00724056-6.5883 371 MAML2 0.000319503 5.15631 UBE2C 0.0194032-6.5569 372 FLJ44112 0.00724617 5.14565 SATL1 0.0765388-6.5555 373 DMKN 0.143319 5.14119 NUF2 0.00527865-6.5546 374 VTRNA1-1 0.0159069 5.1404 KCNG2 0.0887613-6.5508 375 SNORA36B 0.0147946 5.13016 NPY 0.209769-6.5504 376 MIR100 0.0559234 5.12876 ANK1 0.0138006-6.531 377 PAPPA2 0.0625721 5.12491 TMEM63C 0.0220369-6.5116 378 SORBS2 0.033107 5.11971 EME1 0.00270741-6.5093 379 LY6H 0.0667492 5.10817 PRODH 0.128076-6.5082 380 OR14C36 0.112301 5.0827 C2orf71 0.00741665-6.4968 381 FHOD3 0.000974623 5.08169 RASD1 0.023998-6.4947 382 SNORA40 0.0679781 5.07546 NRCAM 0.0154409-6.4914 383 PION 0.00968957 5.04379 CDC6 0.110362-6.4869 384 C4orf19 0.0562559 5.03647 CORO6 0.0752159-6.4822 385 LRRIQ1 0.156587 5.03447 PDE4C 0.0834328-6.4683 386 EFHC2 0.0675668 5.02604 FAM184A 0.0118869-6.4642 387 NFATC4 0.00191619 5.01572 CCNE2 0.00293138-6.4602 388 HDC 0.0352356 5.01192 KCND3 0.00205165-6.4382 389 SLC5A1 0.0624499 4.99909 ONECUT2 0.0809525-6.4368 390 LTBP1 0.112807 4.96585 RELN 0.0920823-6.4248 391 DNAH10 0.0277313 4.9539 LHX3 0.00213916-6.4157 392 EPCAM 0.0970943 4.95128 LEFTY2 0.0260433-6.4125 393 DPYD 0.0719089 4.95125 PLA2G4D 0.00594028-6.3969 394 AGBL2 0.102439 4.95104 DLK2 0.010912-6.3856 395 KLHDC7B 0.075974 4.95054 ZSCAN12L1 0.0376529-6.3854 396 NOSTRIN 0.000152104 4.93964 ARC 0.00264494-6.3806 397 MAPK10 0.014785 4.93106 DOK7 0.00145439-6.3754 398 CACNA1G 0.0793988 4.92614 KCNJ8 0.112762-6.3615 399 OR2M1P 0.0087315 4.92351 SPOCK3 0.0248272-6.3598 400 CLCNKB 0.00564259 4.92086 LINGO4 0.0870525-6.3505 401 ODF4 0.112807 4.91916 C21orf62 0.0732518-6.3434 402 ATHL1 0.0102376 4.91551 HOXA9 0.043135-6.3371 403 CHL1 0.0298052 4.90811 FLVCR2 0.00242539-6.2997 29

404 NNMT 0.0256364 4.89501 C10orf62 0.0267478-6.277 405 SLC8A1 0.10648 4.87052 GALNT9 0.179217-6.2691 406 FLJ37587 0.00563503 4.86282 C12orf34 0.0490729-6.254 407 C1RL 0.00702893 4.85621 NMU 0.100531-6.2296 408 MRVI1 0.000152943 4.85145 COBL 0.0095194-6.2271 409 TCTEX1D4 0.0624816 4.84395 MEGF10 0.00788579-6.2013 410 GLT25D2 0.0637296 4.84068 GADD45G 0.0680213-6.1955 411 ATP8B1 0.0668592 4.83824 NECAB1 0.0493691-6.1939 412 IRX6 0.02287 4.83633 TNFRSF13C 0.0709688-6.1916 413 SNORD96A 0.0456711 4.82669 CCDC21 0.0121995-6.167 414 BOC 0.00205125 4.8237 CELA2B 8.58E-05-6.1602 415 SCTR 0.0233387 4.81268 RXRG 0.123513-6.1342 416 NR2E1 0.0713921 4.80778 RRM2 0.164487-6.1314 417 C1orf173 0.0300102 4.80575 NDST4 0.0236641-6.116 418 FCER1A 0.112159 4.80402 SLC38A3 0.0142319-6.089 419 TCEAL2 0.314381 4.78042 TRIM63 0.0232808-6.0763 420 ALOX12B 0.270644 4.77987 CDC7 0.00557901-6.0485 421 CCDC85B 0.0251995 4.77618 CDCA2 0.0510223-6.0116 422 CDC42EP5 0.00128496 4.77178 RIMS3 0.0450341-6.0083 423 C10orf113 0.174688 4.76997 SLC25A18 0.0835462-5.9963 424 DLG4 0.0358006 4.76914 GRM8 0.0876058-5.996 425 PGPEP1 0.00279081 4.75728 CKB 0.0168016-5.969 426 CES1 0.129729 4.75444 FNDC5 0.0319335-5.9647 427 TCEAL6 0.119112 4.75168 HHIP 0.00462212-5.96 428 PLP1 0.067104 4.74991 APOC2 0.03908-5.96 429 PRDM16 0.0864496 4.74944 CACNG6 0.131848-5.9546 430 SLC13A5 0.336679 4.74342 CAMK2N2 0.084966-5.9363 431 SCARNA11 0.0298052 4.74183 HBQ1 0.100724-5.9339 432 EVPL 0.183446 4.74064 HOXA7 0.0243102-5.9298 433 BEST4 0.0712244 4.72603 GGNBP2 0.0453978-5.9255 434 CDH8 0.111037 4.72394 LOC650137 0.0147946-5.9232 435 C10orf107 0.0391305 4.7212 TMEM233 0.115836-5.9231 436 STK33 0.12292 4.71743 ASB2 0.000261274-5.9149 437 LOC389332 0.0519209 4.71078 ZNF560 0.0869303-5.9076 30

438 NRG2 0.0453872 4.694 GPR37 0.035534-5.903 439 SLC7A8 0.000570005 4.6872 RNF186 0.00202498-5.9006 440 C6orf118 0.0675668 4.67307 POM121L10P 0.123648-5.8985 441 CRISPLD1 0.0553134 4.6638 SYNPO2L 0.084966-5.8849 442 OR2L13 0.0582283 4.66044 SLC7A7 0.00147047-5.8835 443 LRRC16 0.00246561 4.656 FAM71E1 0.0480543-5.8786 444 DCLK1 0.00588305 4.64374 BLCAP 0.0033334-5.8777 445 OSAP 0.00758612 4.62586 FLJ45537 0.0038127-5.8752 446 DBX1 0.0975984 4.62391 CASC5 0.0719674-5.8551 447 SLC16A11 0.0349543 4.61924 MAGEA10 0.419347-5.8493 448 VTRNA1-2 0.166968 4.61041 NKAIN2 0.0921923-5.8398 449 GALR1 0.189718 4.6074 LYG2 0.0399226-5.7995 450 TBX1 0.0658589 4.60156 XIRP2 0.504632-5.7949 451 BLID 0.0159079 4.60063 ASB5 0.29795-5.782 452 WDR16 0.00927404 4.58445 MKRN3 0.112955-5.7811 453 GALIG 0.00409421 4.5775 COX6A2 0.0703379-5.7725 454 CMAH 0.00216897 4.57446 TGM3 0.113232-5.7707 455 SNORD85 0.019388 4.56739 HMX2 0.00025498-5.7619 456 SNORA5A 0.0214956 4.56305 ZNF57 0.000974001-5.7365 457 AHR 0.00128513 4.5544 C19orf15 0.0609461-5.7318 458 C9orf135 0.0819869 4.5512 OMG 0.0718113-5.7287 459 PDE1B 0.000594862 4.55048 SLC24A4 0.00877386-5.7187 460 SAMD5 0.155863 4.54784 LGI2 0.0115107-5.7049 461 MIR1294 0.0960054 4.54405 E2F7 0.00374303-5.7001 462 MRC2 0.00847146 4.54377 POU3F2 0.129884-5.6905 463 ALDH3A1 0.199235 4.54215 DHTKD1 0.00555599-5.685 464 C9orf171 0.106943 4.53871 BYSL 0.047879-5.6847 465 ADAD2 0.0338579 4.53452 ESPL1 0.0456711-5.6826 466 SRD5A2 0.105082 4.53421 TNNI2 0.0665913-5.6805 467 LOC339535 0.251123 4.5282 ZNF233 0.00704223-5.6697 468 RNF39 0.289904 4.52099 DHRS7C 0.26704-5.6656 469 TRIM29 0.201074 4.50835 C20orf55 0.0221066-5.6402 470 SPRR3 0.573007 4.50551 PIF1 0.00732758-5.6389 471 SLFN13 0.0047299 4.50308 TMCC3 0.00557187-5.6317 31

472 MAS1 0.325267 4.50128 CDK5R1 0.000550018-5.6101 473 TMEM102 0.297871 4.49321 PALM2 0.00843566-5.6067 474 ADCY5 0.0985109 4.48842 LHX2 0.32279-5.5977 475 MICA 0.101872 4.4877 TTK 0.019226-5.5906 476 STAT4 0.0144535 4.48697 KIF15 0.105405-5.5898 477 MAGEA4 0.119112 4.48641 ZIM2 0.00377321-5.5847 478 MOV10L1 0.125773 4.48578 C8orf34 0.000555404-5.5684 479 VIPR1 0.0334895 4.48334 CNPY1 0.0137071-5.5509 480 PREX2 0.029584 4.48268 HIST1H3I 0.00360054-5.5095 481 SNORD98 0.0662961 4.47743 EXOC3L 0.00337135-5.477 482 MPL 0.0137071 4.4763 GRWD1 0.0758011-5.455 483 FAM154B 0.0361029 4.471 TRIP13 0.059414-5.4539 484 SFRP2 0.029058 4.46388 DAPL1 0.378948-5.4538 485 LYNX1 0.0590961 4.46201 LILRA3 0.0679781-5.4496 486 CCDC148 0.0802006 4.4614 UPB1 0.111901-5.4469 487 LAMA3 0.0475947 4.45761 MXD3 0.0440306-5.4244 488 SPTB 0.112498 4.45527 SEMA3D 0.0659801-5.4112 489 CTAG1A 0.0318557 4.45062 KRT86 0.159964-5.4042 490 GNAL 0.0468844 4.4464 MSTN 0.0662151-5.3946 491 OVOL2 0.261526 4.44585 RACGAP1 0.00433889-5.3869 492 WDR69 0.314984 4.44267 ENO3 0.00384629-5.3766 493 LMTK3 0.0794846 4.44102 PLK4 0.00564259-5.3711 494 TTC6 0.091815 4.43514 HAS1 0.216671-5.3673 495 MS4A8B 0.171886 4.43036 CCDC141 0.00216897-5.3573 496 FRMD6 0.00176701 4.42964 C4orf39 0.0344745-5.3518 497 PIB5PA 0.0356074 4.42742 CD300C 0.0562709-5.3466 498 CCDC78 0.0774392 4.42656 TFAP2D 0.195981-5.3459 499 FLT4 0.107647 4.42564 IGSF1 0.0215873-5.3344 500 LRRK2 0.00147047 4.42522 CORO7 0.0340917-5.3292 Additional Genes of Interest EPHA4 0.0303776 3.88906 MYCN 0.012638-5.1539 NEBL 0.187722 2.20586 TNNT2 0.0147057-4.9123 PRKAR2B 0.317593 2.12501 FOXO1 0.0164641-4.683 GREM1 0.400277 2.04276 MYOD1 0.08786-4.6427 32